SCHEMBL1885490

SCHEMBL1885490

NC(=O)c1ccc(F)cc1C(F)(F)F.O=S(=O)(O)c1ccc(N2CCN(c3ccccn3)CC2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
POLB P06746 3/20 0.48
MAPT P10636 3/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
KDM4E B2RXH2 3/20 0.47
GAA P10253 3/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HCRTR1 O43613 1/20 0.43
P2RX7 Q99572 1/20 0.43
PKM P14618 1/20 0.42
PARP1 P09874 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
BACE1 P56817 1/20 0.41
TNF P01375 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1888251 0.91 KMT2A (0.42) MAPTMEN1KMT2ASMN1; SMN2PARP1
SCHEMBL4371600 0.89 PKM (0.43) KMT2AKDM4EGAASMN1; SMN2PKM
SCHEMBL1886892 0.89 RPS6KB1 (0.45) LMNAMAPTGAAPKMPARP1
SCHEMBL1883785 0.89 RPS6KB1 (0.43) MAPTSMN1; SMN2PKMPARP1CA12
SCHEMBL4368504 0.89 KMT2A (0.44) KMT2AKDM4EGAASMN1; SMN2PKM
SCHEMBL1883510 0.87 HSD11B1 (0.44) MAPTKDM4EPKMPARP1ALDH1A1
SCHEMBL4370991 0.87 WDR5 (0.48) MAPTMEN1KMT2AGAASMN1; SMN2
SCHEMBL4372077 0.87 CA12 (0.41) MAPTPKMPARP1CA12CA1
SCHEMBL1881316 0.87 KDM4E (0.52) LMNAPOLBMAPTMEN1KMT2A
SCHEMBL4366386 0.85 HSD11B1 (0.44) LMNAMAPTKMT2AKDM4ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939532-B2 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2011-05-10 US claimed
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US claimed
US-7939532-B2 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2011-05-10 US disclosed
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US disclosed
EP-2079719-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2009-07-22 EP disclosed
WO-2008049605-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS STS, TPMT, DPYD LMNA 1709/4885POLB 2710/4885MAPT 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.